Chembio Diagnostics Inc

Chembio Diagnostics — Investor Presentation (August 2019)

24 slides from Chembio Diagnostics's investor presentation, Aug 7, 2019

  1. Slide 1: Corporate Presentation August 2019

    Corporate PresentationAugust 2019 © 2018 Chembio. All Rights Reserved. | # © 2019 Chembio. All Rights Reserved. Page *

  2. Slide 2: Safe Harbor Statement

    Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect manag

  3. Slide 3: Chembio Diagnostics

    We deliver high-quality diagnostic tests that use a small drop of fingertip blood and provide results in approximately 15 minutes © 2019 Chembio. All Rights Reserved. Page * Chembio Diagnostics

  4. Slide 4: DPP HIV 1/2 Assay

    99.8% Sensitivity(1)100% Specificity(1) Patented DPP® Technology Platform (1) Based on fingerstick whole blood samples: DPP® HIV 1/2 Assay Product FeaturesSimple: easy to useFast: results in ~15 minutesReliable: FDA approved, CLIA waivedProduct UniquenessEnhanced sensitivity and specificityAdvanced

  5. Slide 5: DPP technology enhanced through optical analyzer

    DPP® technology is enhanced through use of an optical analyzer Provides data capture, storage, and connectivity (e.g., Bluetooth, cloud, direct)Enables quantitative measurement Drives down level of detection and improves analytical sensitivitySimplifies interpretation of results compared to visually

  6. Slide 6: Lateral Flow Test Market

    Lateral Flow Test Market: $5.5B(1)Expected to grow at 8.2% CAGR(1), reaching $8.2B(1) (2022) © 2019 Chembio. All Rights Reserved. Page * Infectious disease is the largest and fastest growing segment, estimated at $1.4 billion(2) annually and growing at ~10% CAGR(2)Chembio is currently focused on thr

  7. Slide 7: Lateral Flow Infectious Disease Market

    HIV has claimed more than 35 million lives to date, including 940,000 in 2017(1)Approximately 36.9 million people were living with HIV at the end of 2017; 1.8 million people became newly infected in 2017(1)Syphilis = Estimated 18 million prevalent cases and 5.6 million new infections annually(2)Deng

  8. Slide 8: 2019 Corporate Priorities

    1. Expand Commercialization2. Advance R&D Pipeline3. Prepare for Additional Growth 2019 Corporate Priorities © 2019 Chembio. All Rights Reserved. Page *

  9. Slide 9: Expand Commercialization

    Expand Commercialization 1 © 2019 Chembio. All Rights Reserved. Page *

  10. Slide 10: Multiple Growth Drivers

    Increase market penetration in existing marketsUnited StatesBrazilAfricaEurope Register existing and new products into unchartered countries/regionsLatin AmericaSoutheast Asia Multiple Growth Drivers © 2019 Chembio. All Rights Reserved. Page * Expand commercial presenceEuropeUnited States

  11. Slide 11: Expanding our Commercial Presence

    © 2019 Chembio. All Rights Reserved. Page * Colombia S. Africa Germany Malaysia Kenya Expanding our Commercial PresenceDirect sales presence in US, EU, LATAM, Africa, Asia Brazil United States

  12. Slide 12: Expanding Product Approvals Geographically

    Expanding Product Approvals Geographically Product Name U.S. Int’l(1) DPP® HIV 1/2   DPP® HIV-Syphilis Pending FDA Approval  DPP® Syphilis Screen & Confirm  DPP® Dengue-Zika-Chikungunya  DPP® Dengue  DPP® Zika  FDA EUA  DPP® Chikungunya  DPP® Leishmania  STAT-PAK® HIV 1/2   SURE CHECK® H

  13. Slide 13: HIV-Syphilis Presents U.S. Growth Opportunity

    HIV-Syphilis Presents U.S. Growth OpportunityCo-infection and mother-to-child transmission are global health concerns Key AccomplishmentsDeveloped DPP® HIV-Syphilis multiplex testReceived regulatory approvals from ANVISA (Brazil), COFEPRIS (Mexico), CE mark (EU) Completed DPP® HIV-Syphilis U.S. clin

  14. Slide 14: Advance R&D Pipeline

    Advance R&D Pipeline 2 © 2019 Chembio. All Rights Reserved. Page *

  15. Slide 15: Chembio's Infectious Disease Pipeline

    Chembio's Infectious Disease PipelinePresents multiple growth opportunities Product Name Collaborator Phase I(Feasibility) Phase II(Development) Phase III(Verification/Validation) Phase IV(Clinical/Regulatory) Phase V(Commercial Launch) DPP® HIV-Syphilis (US) Submitted FDA PMA Q1 2018 DPP® Dengue (I

  16. Slide 16: Leverage our DPP Technology Platform

    Leverage our DPP® Technology PlatformWhat opportunities do our technology collaborations provide? Expansion into new marketsCancer DiagnosticsConcussion / Traumatic Brain InjuryVeterinaryBroadening application from POC diagnostics to companion diagnosticsDrugsVaccinesCost-effective research & develo

  17. Slide 17: Chembio's Technology Collaborations

    Chembio’s Technology CollaborationsProvides expansion into new markets and fully-funded R&D costs Product Name Collaborator Phase I(Feasibility) Phase II(Development) Phase III(Verification/Validation) Phase IV(Clinical/Regulatory) Phase V(Commercial Launch) DPP® Eosinophilic / Respiratory Received

  18. Slide 18: Why Global Leaders Choose Chembio

    Deep scientific expertise with a proven technology platformSensitive and specificAdvanced multiplexing capabilitiesQuantitative resultsSuccessful track record developing DPP® tests with diverse collaboratorsGlobal commercial companiesGovernmentsNon-governmental organizationsExtensive experience achi

  19. Slide 19: Prepare for Additional Growth

    Prepare for Additional Growth 3 © 2019 Chembio. All Rights Reserved. Page *

  20. Slide 20: Automate U.S. Manufacturing

    Automate U.S. ManufacturingAutomated DPP® line commenced production Q1 2019 EfficientReduces variable costs to produce DPP® testsIntelligentEnhances inspection and quality control via vision-guided, robotic operationFlexibleAllows assembly of various configurations of DPP® tests on a single lineScal

  21. Slide 21: Expand and Improve U.S. Facilities

    Expand and Improve U.S. FacilitiesNew U.S. Headquarters: 555 Wireless Boulevard, Hauppauge, NY © 2019 Chembio. All Rights Reserved. Page * Facility consolidation, expansion and improvement occurs in three phasesPhase 1: Sales, Marketing, Finance, Regulatory, Warehouse, Distribution (H1 2019)Phase 2:

  22. Slide 22: Q2 2019 Financials

    Q2 2019 Financials © 2019 Chembio. All Rights Reserved. Page *

  23. Slide 23: Investment Highlights

    Five-year targets: 2023FY Revenue $100M and 2023YE 50% Gross Margins Proprietary DPP® technology platform with broad diagnostic applications, providing enhanced sensitivity and specificity, advanced multiplexing capabilities, and quantitative results Growing infectious disease business (39%) with on

  24. Slide 24: © 2019 Chembio. All Rights Reserved. Page *

    © 2019 Chembio. All Rights Reserved. Page *

Chembio Diagnostics — Investor Presentation (August 2019) on 6ix